Raddeanin A Inhibits Colorectal Cancer Growth and Ameliorates Oxaliplatin Resistance Through the WNT/β-Catenin Signaling Pathway
Cancer Biotherapy and Radiopharmaceuticals · 2025-01 · 40 (1) · 41-53
DOI: 10.1089/cbr.2024.0061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, online erschienen am 30.01.2025. Verfasst von Junguo Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Oxaliplatin, Drug Resistance, Neoplasm, Wnt Signaling Pathway, Colorectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chemotherapy based on oxaliplatin (OXA) is the first-line treatment for advanced colorectal cancer (CRC), and acquired resistance to OXA is the main reason for clinical treatment failure in CRC.
Methods
To search for compounds that can reverse OXA resistance, we screened a small molecule inhibitor drug library and identified a drug, Raddeanin A (RA), that enhanced the anticancer effect of OXA. Using human CRC cell lines, CRC organoid models, and in vivo subcutaneous tumorigenic studies, we determined that RA inhibits the proliferation of CRC cells by promoting apoptosis and inducing cell cycle arrest.
Results
We constructed OXA-resistant CRC cell lines and demonstrated that RA enhances the sensitivity of these cells to OXA. Further experiments showed that the mechanism by which RA enhanced the anticancer effects of OXA in CRC was by inhibiting the activation of the WNT/β-catenin signaling pathway.
Conclusions
Because RA has been shown to be biocompatible in animal models, there is a possibility that RA could be developed as a sensitizer for resistant cancer cells or as a novel lead compound to enhance the therapeutic efficacy of OXA in resistant CRCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of General Surgery (Gastrointestinal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Geriatrics, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Yanhong Zhang
Zitieren
APA
Chen, J., Zhang, Y., Chen, X., Luo, D., Liu, D., Yu, Z., Lin, Y., He, X., Huang, J., & Lian, L. (2025). Raddeanin A Inhibits Colorectal Cancer Growth and Ameliorates Oxaliplatin Resistance Through the WNT/β-Catenin Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals, 40(1), 41-53. https://doi.org/10.1089/cbr.2024.0061
Vancouver
Chen J, Zhang Y, Chen X, Luo D, Liu D, Yu Z, et al. Raddeanin A Inhibits Colorectal Cancer Growth and Ameliorates Oxaliplatin Resistance Through the WNT/β-Catenin Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals. 2025;40(1):41-53. doi:10.1089/cbr.2024.0061
BibTeX
@article{Chen2025,
author = {Chen, Junguo and Zhang, Yanhong and Chen, Xijie and Luo, Dandong and Liu, Danlin and Yu, Zhaoliang and Lin, Yanyun and He, Xiaosheng and Huang, Juanni and Lian, Lei},
title = {Raddeanin A Inhibits Colorectal Cancer Growth and Ameliorates Oxaliplatin Resistance Through the WNT/β-Catenin Signaling Pathway},
journal = {Cancer Biotherapy and Radiopharmaceuticals},
year = {2025},
volume = {40},
number = {1},
pages = {41--53},
doi = {10.1089/cbr.2024.0061}
}
EUVIMED